3区 · 医学
Article
作者: Rivenzon-Segal, Dalia ; Muller, Kristine ; Schrag, Michael ; Lee, Matt R. ; Xu, Han ; Frohn, Mike ; Siu, Jerry ; Vargas, Hugo M. ; Bürli, Roland W. ; Wong, Min ; Xu, Yang ; Arnett, Heather ; Cee, Victor J. ; Pickrell, Alex ; Gore, Anu ; Buys, Janet ; Lanman, Brian A. ; Horner, Michelle ; Zhang, Xuxia ; McElvain, Michele ; Golden, Jennifer ; Middleton, Scot ; Itano, Andrea ; Fiorino, Mike ; Neira, Susana
The optimization of a series of thiazolopyridine S1P1 agonists with limited activity at the S1P3 receptor is reported. These efforts resulted in the discovery of 1-(3-fluoro-4-(5-(1-phenylcyclopropyl)thiazolo-[5,4-b]pyridin-2-yl)benzyl)azetidine-3-carboxylic acid (5d, AMG 369), a potent dual S1P1/S1P5 agonist with limited activity at S1P3 and no activity at S1P2/S1P4. Dosed orally at 0.1 mg/kg, 5d is shown to reduce blood lymphocyte counts 24 h postdose and delay the onset and reduce the severity of experimental autoimmune encephalomyelitis in rat.